Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2021 | Blinatumomab for consolidation and maintenance in ALL

Robin Foà • 14 Jun 2021
EHA 2021
Acute Lymphoblastic Leukemia Leukemia Antibodies Blinatumomab
GIMEMA LAL2317

Robin Foà, MD, Sapienza University of Rome, Rome, Italy, describes the use of blinatumomab as a consolidation therapy in patients with acute lymphoblastic leukemia (ALL), highlighting it’s current use in patients who are measurable residual disease (MRD)-positive. Prof. Foà also comments on the findings of the GIMEMA LAL2317 trial (NCT03367299) of sequential chemotherapy and blinatumomab to improve MRD response and survival in patients with ALL. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

More from Robin Foà

8:11
The José Carreras award and a history of immunotherapy in Ph+ ALL
Robin Foà • 11 Jun 2023
3:22
The evolution of therapy for Ph+ ALL and Ph- ALL & the role of MRD in this space
Robin Foà • 11 Jun 2023
2:36
Investigating the incidence and outcomes of CNS relapse in patients with ALL
Robin Foà • 23 Mar 2023
10:05
Chemotherapy-free regimens in Ph+ ALL: where are we now and where are we headed?
Robin Foà • 23 Mar 2023

Related Videos

1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
2:25
Optimizing haplo-SCT for the treatment of AML
Arnon Nagler • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals